Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Am J Physiol Cell Physiol ; 326(5): C1482-C1493, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38525537

ABSTRACT

Corneal fibroblasts maintain homeostasis of the corneal stroma by mediating the synthesis and degradation of extracellular collagen, and these actions are promoted by transforming growth factor-ß (TGF-ß) and interleukin-1ß (IL-1ß), respectively. The cornea is densely innervated with sensory nerve fibers that are not only responsible for sensation but also required for physiological processes such as tear secretion and wound healing. Loss or dysfunction of corneal nerves thus impairs corneal epithelial wound healing and can lead to neurotrophic keratopathy. The sensory neurotransmitter substance P (SP) promotes corneal epithelial wound healing by enhancing the stimulatory effects of growth factors and fibronectin. We have now investigated the role of SP in collagen metabolism mediated by human corneal fibroblasts in culture. Although SP alone had no effect on collagen synthesis or degradation by these cells, it promoted the stimulatory effect of TGF-ß on collagen type I synthesis without affecting that of IL-1ß on the expression of matrix metalloproteinase-1. This effect of SP on TGF-ß-induced collagen synthesis was accompanied by activation of p38 mitogen-activated protein kinase (MAPK) signaling and was attenuated by pharmacological inhibition of p38 or of the neurokinin-1 receptor. Our results thus implicate SP as a modulator of TGF-ß-induced collagen type I synthesis by human corneal fibroblasts, and they suggest that loss of this function may contribute to the development of neurotrophic keratopathy.NEW & NOTEWORTHY This study investigates the role of substance P (SP) in collagen metabolism mediated by human corneal fibroblasts in culture. We found that, although SP alone had no effect on collagen synthesis or degradation by corneal fibroblasts, it promoted the stimulatory effect of transforming growth factor-ß on collagen type I synthesis without affecting that of interleukin-1ß on the expression of matrix metalloproteinase-1.


Subject(s)
Fibroblasts , Interleukin-1beta , Substance P , Transforming Growth Factor beta , p38 Mitogen-Activated Protein Kinases , Humans , Substance P/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism , Transforming Growth Factor beta/metabolism , Fibroblasts/metabolism , Fibroblasts/drug effects , Cells, Cultured , Interleukin-1beta/metabolism , Collagen Type I/metabolism , Collagen Type I/biosynthesis , Receptors, Neurokinin-1/metabolism , Cornea/metabolism , Cornea/drug effects , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 1/genetics , Collagen/metabolism , Collagen/biosynthesis , Signal Transduction/drug effects , Corneal Stroma/metabolism , Corneal Stroma/drug effects , Corneal Keratocytes/metabolism , Corneal Keratocytes/drug effects
2.
Ophthalmology ; 119(6): 1111-9, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22381810

ABSTRACT

OBJECTIVE: To evaluate the diagnostic value of real-time polymerase chain reaction (PCR) for detecting Acanthamoeba in eyes diagnosed with Acanthamoeba keratitis (AK) by conventional tests. In addition, to determine the preoperative prognosis-determining factors in eyes with AK. DESIGN: Retrospective, cross-sectional study. PARTICIPANTS: A total of 104 eyes of 103 patients who were diagnosed with AK or with bacterial or bacteria-associated keratitis (BK) by conventional tests. METHODS: Twenty-nine eyes with AK and 75 eyes with BK were evaluated for Acanthamoeba and bacterial DNA by real-time PCR. The Acanthamoeba copy numbers, bacterial load, and clinical parameters in the patients with AK were assessed for those significantly associated with poor outcome, that is, final visual acuity of <20/50 or requiring keratoplasty, by logistic regression analysis. MAIN OUTCOME MEASURES: Acanthamoeba DNA copy number, bacterial DNA copy number, and odds ratio (OR) for poor prognosis. RESULTS: The detection of amoebic DNA was 50 times more sensitive by real-time PCR than by conventional cyst counting. The Acanthamoeba copy numbers at the first visit (mean: 4.7×10(5)±3.2×10(5) copies) were significantly correlated with the AK stage, and both were significant risk factors for a poor outcome. The Acanthamoeba DNA copy numbers at the first visit and AK stage had a significantly high risk for poor outcome (OR of Acanthamoeba DNA copy per logarithm of copy numbers: 3.48, 95% confidence interval [CI], 1.04-111.63, P<0.05; OR of AK stage: 2.8 per stage increase, 95% CI, 1.07-7.30, P<0.05, after adjustment of age). In the AK cases with poor outcome, the amoebic DNA was not reduced by more than 90% after 1 month of treatment. The weak amoebic reduction was significantly associated with advanced AK stages or previous use of steroids. Bacterial 16S rDNA was detected in 53.6% of the eyes with AK, but it was not associated with any risk for refractoriness. CONCLUSIONS: Real-time PCR was effective in detecting and managing AK. The Acanthamoeba copy number and AK stage at the first visit were significantly associated with poor outcome. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.


Subject(s)
Acanthamoeba Keratitis/diagnosis , Acanthamoeba/genetics , DNA, Protozoan/analysis , Acanthamoeba/isolation & purification , Acanthamoeba Keratitis/parasitology , Adult , Cornea/parasitology , Cornea/pathology , Corneal Ulcer/diagnosis , Corneal Ulcer/microbiology , Cross-Sectional Studies , DNA Copy Number Variations , Female , Humans , Male , Middle Aged , Parasite Load , Predictive Value of Tests , Prognosis , Real-Time Polymerase Chain Reaction , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity , Visual Acuity/physiology
3.
Invest Ophthalmol Vis Sci ; 60(8): 2895-2903, 2019 07 01.
Article in English | MEDLINE | ID: mdl-31266061

ABSTRACT

Purpose: The proinflammatory cytokine interleukin (IL)-1 is implicated in corneal ulceration and promotes collagen degradation by corneal fibroblasts cultured in a three-dimensional (3D) collagen gel. Epigallocatechin-3-gallate (EGCG), the principal polyphenol in extracts of green tea, has various beneficial health effects, some of which appear to be mediated through direct or indirect inhibition of protease activity. We therefore examined the effect of EGCG on IL-1ß-induced collagen degradation by corneal fibroblasts embedded in a collagen gel. Methods: Human corneal fibroblasts were cultured in a type I collagen gel. Collagen degradation was assessed by measurement of hydroxyproline in acid hydrolysates of culture supernatants. The expression of urokinase-type plasminogen activator (uPA) was examined by real-time and RT-PCR analysis and by fibrin zymography, and that of the collagenase matrix metalloproteinase 1 (MMP1) was detected by immunoblot analysis. Results: EGCG inhibited IL-1ß-induced, plasminogen-dependent collagen degradation by corneal fibroblasts in a concentration-dependent manner. It also attenuated the IL-1ß-induced expression of uPA at both mRNA and protein levels. EGCG inhibited the IL-1ß-induced conversion of exogenous plasminogen to plasmin as well as the plasminogen-dependent activation of pro-MMP1 in the 3D cultures without a substantial effect on pro-MMP1 abundance. Conclusions: EGCG inhibits IL-1ß-induced collagen degradation by corneal fibroblasts, with this effect likely being mediated by suppression of the upregulation of uPA, the uPA-mediated conversion of plasminogen to plasmin, and the plasmin-mediated activation of pro-MMP1. EGCG thus warrants further investigation as a potential treatment for corneal ulcer.


Subject(s)
Antioxidants/pharmacology , Catechin/analogs & derivatives , Collagen/metabolism , Corneal Keratocytes/drug effects , Interleukin-1beta/antagonists & inhibitors , Urokinase-Type Plasminogen Activator/genetics , Catechin/pharmacology , Cell Survival/drug effects , Cells, Cultured , Corneal Keratocytes/metabolism , Dose-Response Relationship, Drug , Fibrin/metabolism , Fibrinolysin/metabolism , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Humans , Hydroxyproline/metabolism , Interleukin-1beta/pharmacology , Matrix Metalloproteinase 1/metabolism , NF-kappa B/metabolism , Real-Time Polymerase Chain Reaction
4.
Cornea ; 27(3): 334-8, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18362663

ABSTRACT

PURPOSE: To determine the efficacy of A-5021, a new analogue of acyclovir, on murine herpetic keratitis. METHODS: Herpes simplex virus type 1 (strain CHR3) was inoculated onto bilateral scarified BALB/c corneas. Clinical scores on the corneas treated with A-5021 eyedrops were compared with those obtained from the treatment with 3% acyclovir eye ointment by slit lamp microscopy. Virus titers of the trigeminal ganglia and eyeballs were quantitated on Vero cell monolayers. Mice treated with saline or a white petroleum jelly were used as controls. RESULTS: A-5021 eyedrops significantly suppressed both corneal epithelial and stromal lesions at all concentrations used. Clinical scores on the epithelium and stroma treated with 0.1% A-5021 were equivalent to those with 3% acyclovir treatment. When compared with the non-drug-treated control mice, virus titers in the eyeballs and trigeminal ganglia in A-5021- and acyclovir-treated mice were significantly less than those in controls. CONCLUSIONS: A-5021 eyedrops, which are easily applied onto the affected cornea, ameliorated clinical scores and suppressed virus growth. It is a promising alternative treatment of herpetic keratitis.


Subject(s)
Acyclovir/analogs & derivatives , Antiviral Agents/pharmacology , Disease Models, Animal , Guanine/analogs & derivatives , Herpesvirus 1, Human/drug effects , Keratitis, Herpetic/prevention & control , Acyclovir/pharmacology , Animals , Chlorocebus aethiops , Female , Guanine/chemistry , Guanine/pharmacology , Herpesvirus 1, Human/physiology , Keratitis, Herpetic/virology , Mice , Mice, Inbred BALB C , Ophthalmic Solutions/pharmacology , Trigeminal Ganglion/virology , Vero Cells/virology
5.
Semin Ophthalmol ; 23(4): 241-7, 2008.
Article in English | MEDLINE | ID: mdl-18584562

ABSTRACT

To compare the efficacies of valacyclovir (VCV) and acyclovir (ACV) on murine herpetic epithelial keratitis, mice inoculated with herpes simplex virus type 1(HSV-1) strain McKrae were divided into 6 treatment groups: oral VCV 50 mg/kg and 100 mg/kg, oral ACV 50 mg/kg, ACV eye ointment (EO), ACV eye drops (ED), and placebo. Keratitis scores showed that oral VCV 50 mg/kg, oral ACV, and ACV ED had equivalent efficacies, while oral VCV 100 mg/kg was as efficacious as ACV EO during acute infection. Each treatment group was further divided into the stimulated group with HSV-1 reactivation by immunosuppressant drugs and hyperthermia, and the non-stimulated group without reactivation. We assessed the virus titers in tissues by plaque assay and HSV DNA copy number in the trigeminal ganglia (TG) by real time polymerase chain reaction (PCR). Results showed that the virus titers in the tissues were lowered after reactivation, and the oral VCV group with reactivation had significantly reduced DNA copy number in the TG than the same treatment group without reactivation. In conclusion, oral VCV is as efficacious as ACV EO and significantly suppresses HSV-1 reactivation.


Subject(s)
Acyclovir/analogs & derivatives , Acyclovir/therapeutic use , Antiviral Agents/therapeutic use , Epithelium, Corneal/virology , Herpesvirus 1, Human/physiology , Keratitis, Herpetic/drug therapy , Valine/analogs & derivatives , Animals , DNA, Viral/genetics , Female , Gene Dosage , Keratitis, Herpetic/virology , Mice , Mice, Inbred BALB C , Reverse Transcriptase Polymerase Chain Reaction , Trigeminal Ganglion/virology , Valacyclovir , Valine/therapeutic use , Virus Activation/drug effects
6.
Cornea ; 25(10 Suppl 1): S64-7, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17001196

ABSTRACT

PURPOSE: To examine the efficacy of valaciclovir (VACV) oral formulation as an alternative to topical treatments in a case of herpetic keratitis. METHODS: The patient was a 61-year-old man who presented with dendritic keratitis in his left eye. After recognizing his difficulty in using eye ointment, we prescribed oral VACV 500 mg tablets twice daily for 7 days. We also describe our experiments with orally administered VACV in a mouse model of this disease. In this study, 143 Balb/c mice were inoculated with herpes simplex virus type 1 (HSV)-1 in each eye and treated with oral VACV 50 or 100 mg/kg twice daily, oral acyclovir (ACV) 50 mg/kg 5 times/d, 3% ACV eye ointment (ACV-O) 5 times/d, 3% ACV eye drops 5 times/d, or control for 5 days. RESULTS: After 7 days, the patient's lesion was observed healed. Corrected left visual acuity was also improved, and HSV DNA was below detectable level. In the mouse study, slit-lamp examination on days 3, 4, 5, and 7 revealed that all 5 ACV and VACV treatment groups were significantly more effective in improving symptoms of herpetic epithelial keratitis versus control (P < 0.05). Moreover, VACV 100 mg/kg was superior to other treatments. Viral titers in mouse eyeball and trigeminal ganglia were lowest in the VACV 100 mg/kg group versus other treatment groups. CONCLUSION: Our case example suggests that when frequent application, blurred vision, and foreign body sensation after ACV-O application cause difficulty for patients to follow treatment, oral VACV might be an effective and safe option for patients with herpetic keratitis.


Subject(s)
Acyclovir/analogs & derivatives , Antiviral Agents/therapeutic use , Keratitis, Dendritic/drug therapy , Valine/analogs & derivatives , Acyclovir/therapeutic use , Administration, Oral , Animals , Cornea/virology , DNA, Viral/analysis , Disease Models, Animal , Gene Dosage , Herpesvirus 1, Human/genetics , Humans , Keratitis, Dendritic/virology , Keratitis, Herpetic/drug therapy , Male , Mice , Mice, Inbred BALB C , Middle Aged , Polymerase Chain Reaction , Prodrugs/therapeutic use , Valacyclovir , Valine/therapeutic use
7.
Cornea ; 35 Suppl 1: S59-S64, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27661072

ABSTRACT

Keratocytes, corneal resident cells in the corneal stroma, exist between collagen lamellae and maintain the corneal stromal structure. When the corneal stroma is damaged, keratocytes are transformed to myofibroblasts to aid corneal wound healing by phagocytizing debris. Keratocytes and extracellular collagen influence each other because keratocytes cultured in a 3D collagen gel undergo morphological changes and keratocytes produce metalloproteases that degrade extracellular collagen. IL-1 and plasminogen are critical mediators for collagen degradation. The plasminogen system contributes to tissue repair by activating matrix metalloproteinases (MMPs), releasing growth factors from the extracellular matrix and extracellular matrix degradation. Urokinase-type plasminogen activator (uPA) is thought to be involved in corneal disorders and regulates corneal wound healing. uPA is a serine protease synthesized by various cells such as corneal epithelial cells, corneal fibroblasts, vascular endothelial cells, smooth muscle cells, monocytes, macrophages, and malignant tumor cells of different origins. Here, we review the role of uPA in corneal stromal wound healing. uPA is expressed in leukocytes and corneal fibroblasts in the corneas of patients with corneal ulcerations suggesting it is a key regulator of corneal stromal wound healing. uPA is directly involved in plasmin-mediated collagen degradation induced by IL-1. Moreover, uPA is critically involved in promoting leukocyte infiltration in corneal inflammation by activating MMP-9. This activation is presumably directly and indirectly mediated by the plasminogen/plasmin cascade. Moreover, uPA mediates the release of inflammatory cytokines from corneal fibroblasts to promote leukocyte infiltration.


Subject(s)
Collagen/metabolism , Corneal Keratocytes/metabolism , Keratitis/metabolism , Urokinase-Type Plasminogen Activator/physiology , Corneal Stroma/metabolism , Cytokines/metabolism , Humans , Matrix Metalloproteinases/metabolism , Wound Healing/physiology
8.
J Ocul Pharmacol Ther ; 21(6): 463-74, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16386088

ABSTRACT

PURPOSE: The aim of this study was to evaluate a series of dipeptide monoester ganciclovir (GCV) prodrugs with the goal of improving ocular bioavailability of GCV from topical ophthalmic solutions. METHODS: Solubility, logP, pH-stability profile, permeability, interaction with corneal peptide transporter, and in vivo efficacy against herpes simplex virus type 1 (HSV-1) ocular disease in the rabbit model were studied. RESULTS: Val-Val-GCV, Tyr-Val-GCV, and Gly-Val-GCV were more stable in aqueous solution than Val-GCV, showing no measurable degradation even after 7 d at 37 degrees C, within the pH range of 1.4-5.4. Tyr-Val-GCV and Val-Tyr-GCV were the most lipophilic among the prodrugs synthesized and were predicted to have an n-octanol/water partition coefficient 33 times greater than that of GCV. All of the prodrugs had a much higher aqueous solubility than the parent drug. Transcorneal permeability of Val-GCV and Val-Val-GCV was seven- to eightfold greater than that of GCV, in the presence of a proton gradient, and was significantly decreased in the presence of Gly-Pro. Val-Val-GCV (1% w/v) provided significantly better therapeutic activity than trifluorothymidine (1% w/v) against HSV-1 epithelial keratitis and equivalent therapeutic activity against stromal keratitis in the rabbit eye model. CONCLUSIONS: Val-Val-GCV demonstrates excellent corneal permeability and chemical stability, high aqueous solubility, and substantial in vivo antiviral activity against the HSV-1.


Subject(s)
Antiviral Agents/therapeutic use , Dipeptides/therapeutic use , Ganciclovir/analogs & derivatives , Ganciclovir/therapeutic use , Herpesvirus 1, Human/drug effects , Keratitis, Herpetic/drug therapy , Prodrugs/therapeutic use , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/chemistry , Antiviral Agents/pharmacokinetics , Biological Availability , Biological Transport , Chromatography, High Pressure Liquid , Corneal Stroma/drug effects , Corneal Stroma/metabolism , Corneal Stroma/virology , Dipeptides/administration & dosage , Dipeptides/chemistry , Dipeptides/pharmacokinetics , Drug Stability , Epithelium, Corneal/drug effects , Epithelium, Corneal/metabolism , Epithelium, Corneal/virology , Esters , Ganciclovir/administration & dosage , Ganciclovir/chemistry , Ganciclovir/pharmacokinetics , Instillation, Drug , Keratitis, Herpetic/virology , Male , Molecular Structure , Ophthalmic Solutions , Permeability , Prodrugs/administration & dosage , Prodrugs/chemistry , Prodrugs/pharmacokinetics , Rabbits , Solubility
9.
Cornea ; 30(11): 1233-7, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21955634

ABSTRACT

PURPOSE: Using real-time polymerase chain reaction (PCR), we detected Acanthamoeba and monitored the changes in Acanthamoeba DNA copy number over the treatment course in patients suspected of Acanthamoeba keratitis (AK). METHODS: Subjects were 6 patients (average age, 26.2 years) suspected of AK at the Kinki University Outpatient Clinic. For detection of Acanthamoeba, patients' corneal scrapings were collected for smear analysis, culture, and real-time PCR. After the diagnosis of AK was confirmed, treatment was initiated based on the quantitative result of the real-time PCR. RESULTS: Both the smear and culture were positive for Acanthamoeba in 4 cases and negative in 2 cases (agreement in 3 cases and disagreement in 2 cases). By real-time PCR, all 6 cases were positive for Acanthamoeba with an average DNA copy number of 4.8 ± 9.1 × 10 copies per sample. We further monitored the variation in the Acanthamoeba DNA copy number over the treatment course and successfully treated all the patients. DNA copy number provided a parallel with other clinical features of AK. CONCLUSIONS: Real-time PCR can be a useful method for a rapid and precise diagnosis of AK. Moreover, utility of the Acanthamoeba DNA copy number obtained by real-time PCR can help ophthalmologists in making the best treatment decision.


Subject(s)
Acanthamoeba Keratitis/diagnosis , Acanthamoeba Keratitis/drug therapy , Acanthamoeba/isolation & purification , Cornea/parasitology , Real-Time Polymerase Chain Reaction , Acanthamoeba/genetics , Acanthamoeba Keratitis/parasitology , Adult , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/therapeutic use , Chlorhexidine/administration & dosage , Chlorhexidine/therapeutic use , Contact Lenses, Hydrophilic/parasitology , DNA Copy Number Variations , DNA, Protozoan/genetics , Female , Humans , Male , Miconazole/administration & dosage , Miconazole/therapeutic use , Ophthalmic Solutions , Young Adult
10.
Arch Ophthalmol ; 128(5): 535-40, 2010 May.
Article in English | MEDLINE | ID: mdl-20457973

ABSTRACT

OBJECTIVE: To detect and quantitate the causative pathogens in patients with corneal ulcer using real-time polymerase chain reaction (PCR) by cycling probe. DESIGN: Clinical and laboratory study of 40 eyes of 40 patients diagnosed with corneal ulcer. Two methods were used for pathogen detection: bacterial culture and real-time PCR with the patient's corneal scrapings. Probes and primers of real-time PCR were designed to be pathogen specific for simultaneous detection of Staphylococcus aureus, Staphylococcus pneumoniae, Pseudomonas aeruginosa, methicillin-resistant S aureus, Candida species, and Fusarium species. Results by both methods were evaluated and compared. RESULTS: Of 40 eyes, 20 eyes had the same pathogens detected by both methods and those were S aureus (3 eyes; mean [SE], 3.8 [1.3] x 10(1) copies/sample), S pneumoniae (5 eyes; mean [SE], 5.6 [5.1] x 10(3) copies/sample), P aeruginosa (8 eyes; 5.1 [4.0] x 10(3) copies/sample), methicillin-resistant S aureus (1 eye; 1.0 x 10(2) copies/sample), and Candida species (3 eyes; mean [SE], 8.8 [4.9] x 10(3) copies/sample). Six eyes showed negative results by both methods. Results of both methods disagreed in 14 eyes; specifically, 11 had positive PCR results only, 2 had positive culture results only, and 1 eye had positive results for different pathogens. CONCLUSIONS: The real-time PCR assay can simultaneously detect and quantitate bacterial and fungal pathogens in patients with corneal ulcer. Real-time PCR can be a fast diagnostic tool and may be useful as an adjunct to identify potential pathogens.


Subject(s)
Bacteria/isolation & purification , Corneal Ulcer/diagnosis , Eye Infections, Bacterial/diagnosis , Eye Infections, Fungal/diagnosis , Fungi/isolation & purification , Polymerase Chain Reaction/methods , Adolescent , Adult , Aged , Aged, 80 and over , Bacteria/genetics , Bacterial Typing Techniques/methods , Corneal Ulcer/microbiology , DNA Primers , DNA Probes , Eye Infections, Bacterial/microbiology , Eye Infections, Fungal/microbiology , Female , Fungi/genetics , Humans , Male , Middle Aged , Mycological Typing Techniques/methods , Sensitivity and Specificity , Young Adult
11.
Curr Eye Res ; 34(3): 171-6, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19274523

ABSTRACT

PURPOSE: To examine the effects of COX inhibitors on suppressing HSV-1 reactivation in a mouse model. METHODS: BALB/c mice were latently infected with HSV-1 and treated by 0.1% bromfenac Na eye drops, 0.1% pranoprofen eye drops, 0.1 mg oral etodolac 4 times/day, and saline for 4 days. After reactivating the latent HSV-1, we swabbed the mouse ocular surface for the culture of the infectious virus and assessed the viral loads in the eyes and trigeminal ganglia (TGs) using real-time PCR to determine the treatment efficacies. RESULTS: With stimulated reactivation, 10 of 24 (41.7%), 5 of 10 (50.0%), 17 of 25 (68%), and 16 of 22 eyes (72.7%) showed positive swab results in the bromfenac Na, etodolac, pranoprofen, and saline groups, respectively; and a significant difference was seen only between the bromfenac Na and saline groups (p = 0.033). None of the three drug-treated groups showed any significant difference from the saline group in the viral DNA in the eyes and TGs (p > 0.05). CONCLUSIONS: Bromfenac Na eye drops can suppress HSV-1 reactivation.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cornea/virology , Cyclooxygenase 2 Inhibitors/therapeutic use , Herpesvirus 1, Human/physiology , Keratitis, Herpetic/virology , Trigeminal Ganglion/virology , Virus Activation/drug effects , Animals , Benzophenones/therapeutic use , Benzopyrans/therapeutic use , Bromobenzenes/therapeutic use , Cornea/innervation , DNA, Viral/analysis , Disease Models, Animal , Etodolac/therapeutic use , Female , Gene Dosage , Herpesvirus 1, Human/isolation & purification , Keratitis, Herpetic/drug therapy , Mice , Mice, Inbred BALB C , Propionates/therapeutic use , Reverse Transcriptase Polymerase Chain Reaction , Viral Load , Virus Latency/physiology
12.
Clin Ophthalmol ; 3: 553-7, 2009.
Article in English | MEDLINE | ID: mdl-19898627

ABSTRACT

PURPOSE: The objective of the study was to compare the intraocular penetration levels of the newer fluoroquinolones, moxifloxacin, gatifloxacin, and levofloxacin in the rabbit's cornea, aqueous humor, and conjunctiva after topical instillation. METHODS: 0.5% moxifloxacin, 0.3% gatifloxacin, and 0.5% levofloxacin were instilled in random sequence in both eyes of nine New Zealand White rabbits at two-minute intervals. Instillation was repeated every 15 minutes for a total of three drops of each fluoroquinolone per eye. Three additional animals had only moxifloxacin instilled bilaterally using the same schedule. Sixty minutes after the final instillation, the rabbits were sacrificed for determination of corneal, aqueous humor, and conjunctival fluoroquinolone concentrations using high-performance liquid chromatography. RESULTS: Moxifloxacin achieved significantly higher concentrations than levofloxacin and gatifloxacin in the cornea (P = 0.0102 and P = 0.0006, respectively), aqueous humor (P = 0.0015 and P < 0.0001, respectively), and conjunctiva (P = 0.0191 and P = 0.0236, respectively). CONCLUSIONS: 0.5% moxifloxacin eyedrops provided superior intraocular penetration in rabbits' eyes compared with the two other fluoroquinolones, 0.5% levofloxacin and 0.3% gatifloxacin.

SELECTION OF CITATIONS
SEARCH DETAIL